BACKGROUND/AIM: This study analyzed the characteristics of patients with COVID-19 with major events during the first days of hospitalization. PATIENTS AND METHODS: This is a retrospective analysis of prospectively collected data from consecutive patients admitted to two hospitals in Athens, Greece. The characteristics of patients with COVID-19 who suffered the primary endpoint (venous thromboembolic events, intubation, and death) during the first days of hospitalization were analyzed. RESULTS: Among 95 patients included in the analysis, 21 presented with major adverse events during a median follow-up of 13 days. More than 50% of these patients presented with a major event during the first 3 days. Anticoagulation treatment was inversely associated with the cumulative incidence of the primary endpoint [hazard ratio=0.16 (95% confidence interval=0.06-0.47)]. Patients with major events were older, with lower baseline SatO2, and higher number of Wells' criteria and Charlson comorbidity index. Among these patients, those with hypertension were at higher risk for early occurrence of events (≤ first three days of hospitalization). CONCLUSION: Major adverse events may occur early in hospitalized patients with COVID-19 with a high-risk profile. Anticoagulation treatment appears to reduce this risk and thus prompt thromboprophylaxis should be employed in these patients.
BACKGROUND/AIM: This study analyzed the characteristics of patients with COVID-19 with major events during the first days of hospitalization. PATIENTS AND METHODS: This is a retrospective analysis of prospectively collected data from consecutive patients admitted to two hospitals in Athens, Greece. The characteristics of patients with COVID-19 who suffered the primary endpoint (venous thromboembolic events, intubation, and death) during the first days of hospitalization were analyzed. RESULTS: Among 95 patients included in the analysis, 21 presented with major adverse events during a median follow-up of 13 days. More than 50% of these patients presented with a major event during the first 3 days. Anticoagulation treatment was inversely associated with the cumulative incidence of the primary endpoint [hazard ratio=0.16 (95% confidence interval=0.06-0.47)]. Patients with major events were older, with lower baseline SatO2, and higher number of Wells' criteria and Charlson comorbidity index. Among these patients, those with hypertension were at higher risk for early occurrence of events (≤ first three days of hospitalization). CONCLUSION: Major adverse events may occur early in hospitalized patients with COVID-19 with a high-risk profile. Anticoagulation treatment appears to reduce this risk and thus prompt thromboprophylaxis should be employed in these patients.
Authors: Behnood Bikdeli; Mahesh V Madhavan; David Jimenez; Taylor Chuich; Isaac Dreyfus; Elissa Driggin; Caroline Der Nigoghossian; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Joseph A Caprini; Alfonso J Tafur; John R Burton; Dominic P Francese; Elizabeth Y Wang; Anna Falanga; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; P Gabriel Steg; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip Journal: J Am Coll Cardiol Date: 2020-04-17 Impact factor: 24.094
Authors: Grigoris T Gerotziafas; Mariella Catalano; Mary-Paula Colgan; Zsolt Pecsvarady; Jean Claude Wautrecht; Bahare Fazeli; Dan-Mircea Olinic; Katalin Farkas; Ismail Elalamy; Anna Falanga; Jawed Fareed; Chryssa Papageorgiou; Rosella S Arellano; Petros Agathagelou; Darco Antic; Luciana Auad; Ljiljana Banfic; John R Bartolomew; Bela Benczur; Melissa B Bernardo; Francesco Boccardo; Renate Cifkova; Benilde Cosmi; Sergio De Marchi; Evangelos Dimakakos; Meletios A Dimopoulos; Gabriel Dimitrov; Isabelle Durand-Zaleski; Michael Edmonds; Essam Abo El Nazar; Dilek Erer; Omar L Esponda; Paolo Gresele; Michael Gschwandtner; Yongquan Gu; Mónica Heinzmann; Naomi M Hamburg; Amer Hamadé; Noor-Ahmed Jatoi; Oguz Karahan; Debora Karetova; Thomas Karplus; Peter Klein-Weigel; Endre Kolossvary; Matija Kozak; Eleftheria Lefkou; Gianfranco Lessiani; Aaron Liew; Antonella Marcoccia; Peter Marshang; George Marakomichelakis; Jiri Matuska; Luc Moraglia; Sergio Pillon; Pavel Poredos; Manlio Prior; David Raymund K Salvador; Oliver Schlager; Gerit Schernthaner; Alexander Sieron; Jonas Spaak; Alex Spyropoulos; Muriel Sprynger; Dusan Suput; Agata Stanek; Viera Stvrtinova; Andrzej Szuba; Alfonso Tafur; Patrick Vandreden; Panagiotis E Vardas; Dragan Vasic; Miikka Vikkula; Paul Wennberg; Zhenguo Zhai Journal: Thromb Haemost Date: 2020-09-13 Impact factor: 5.249